Echelon Biosciences granted US Patent for PI3K reinforcing its leadership in the commercialization of cancer assays
June 19 2006 - 8:00AM
PR Newswire (US)
SALT LAKE CITY, June 19 /PRNewswire-FirstCall/ -- Echelon
Biosciences Inc. announces the allowance in the U.S. of its patent
application covering non- radioactive, competitive
phosphatidylinositol 3-kinase (PI3-K) assays. This patent
reinforces Echelon's leadership position in the phospholipids
research space, is the first patent allowance of its kind, and
strengthens the oncology synergy within Echelon's parent company,
AEterna Zentaris (NASDAQ:AEZS). PI3-K is a key cellular enzyme and
is often altered in diseases, leading to abnormal cell growth in
cancer and pathological cellular response in inflammation.
Considerable research is being done to determine its importance and
potential as a target for therapeutic development. Echelon's PI3-K
competitive assay patent exemplifies Echelon's unique leadership
role with scientists investigating PI3-K as a therapeutic target
for drug development. Any competitive PI3-K assay employed for use
or sale in the U.S. will require use of Echelon's assay reagents or
a license to this important patent. Echelon offers a family of
competitive PI3-K assays to assist in both primary cellular
research and high throughput (HTS) compound screens for drug
discovery in pharmaceutical and biotechnology companies. Assay
formats offered by Echelon include ELISA, fluorescence-polarization
(FP), AlphaScreen(TM)(x), and its most recent TRue-FRET(TM)
formats. These assay kits are complemented by Echelon's new
generation labeled phosphoinositides branded Glo-PIPs(TM) which are
labeled with BODIPY(R)-FL, BODIPY(R)-TMR, or biotin. Given its
notice of allowance, Echelon expects this patent to issue in the
U.S. in the next few months. Echelon also has a pending application
related to this one and expects additional claims to issue in the
near future. A related Canadian patent application is in the review
process. About Echelon Echelon Biosciences Inc. of Salt Lake City,
Utah, is a wholly owned subsidiary of AEterna Zentaris
(NASDAQ:AEZS) of Quebec City, Quebec, a growing global
biopharmaceutical company engaged in the discovery, development and
marketing of therapies for cancer and endocrine disorders. Echelon
Biosciences Inc. is a leader in the field of lipid research and
lipid-protein interactions that are essential top-level regulators
in numerous cell signaling cascades. Abnormal signaling cascades
lead to many diseases like cancer, inflammation, diabetes, and
cardiovascular disease. Echelon has been a top supplier of research
information, lipid signaling assay and reagent technology for
years. It also has an early-stage program in anti-infective
development, targeting a novel pathway found in many problematic
Gram negative bacteria. AlphaScreen(TM) is a trademark of
PerkinElmer Life Sciences BODIPY is a trademark of Molecular
Probes/Invitrogen True-FRET(TM) and Glo-PIPs(TM) are trademarks of
Echelon Biosciences Inc. DATASOURCE: AETERNA ZENTARIS INC.
(FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA CONTACT: Echelon
contact information: (801) 588-0455, http://www.echelon-inc.com/;
W. Tim Miller, President ; John B. Wirthlin, Dir. Business
Development ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw.
Copyright
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024